Develop and manufacture mineral-based skincare products. Create and produce makeup products with clean ingredients. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 20% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $23.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 31.9× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 13% of them.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 9 buys and 2 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.81. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 4/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 12/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, SLSN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SLSN does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: earnings execution.